MIAMI, Dec. 14, 2016 -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NASDAQ:NCLH) (“NCLH”), today announced the results of its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of its 5.25% senior notes due 2019 (the “5.25% Senior Notes”) having an aggregate outstanding principal amount of $680.0 million. The Tender Offer expired at 5:00 p.m., New York City time, on December 9, 2016.
NCLC has accepted for purchase approximately $394.2 million (or approximately 57.96%) of the 5.25% Senior Notes. NCLC has paid all holders of the 5.25% Senior Notes accepted for purchase in the Tender Offer $1,029.25 per $1,000 principal amount of 5.25% Senior Notes tendered, plus accrued and unpaid interest to, but not including, the settlement date, which is December 14, 2016.
NCLC funded the payment for the tendered and accepted 5.25% Senior Notes with the net proceeds from its previously announced offering of $700.0 million aggregate principal amount of its 4.750% senior notes due 2021.
Barclays Capital Inc. acted as the dealer manager for the Tender Offer. The information agent and tender agent was D.F. King & Co., Inc. Questions regarding the Tender Offer should be directed to Barclays Capital Inc. at (800) 438-3242 or (212) 528-7581.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward- looking statements include, without limitation, statements concerning the debt offering and the tender offer and any statement that may predict, forecast, indicate, or imply future results, performance, or achievements. Forward-looking statements involve risks and uncertainties, including but not limited to economic, competitive, and technological factors outside NCLC’s or NCLH’s control that may cause NCLC’s or NCLH’s business, strategy, or actual results to differ materially from the forward-looking statements. You should not place undue reliance on forward-looking statements as a prediction of actual results. For information about the risks and uncertainties associated with the NCLC’s or NCLH’s business, please refer to NCLH’s and NCLC’s filings with the Securities and Exchange Commission. NCLC and NCLH expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.
Investor Relations Contact Andrea DeMarco (305) 468-2339 [email protected]


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Anta Sports Expands Global Footprint With Strategic Puma Stake
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



